iSpecimen (NASDAQ:ISPC) Shares Down 3.7% – Here’s Why

iSpecimen Inc. (NASDAQ:ISPC)’s stock price was down 3.7% during trading on Thursday . The company traded as low as $1.83 and last traded at $1.83. Approximately 23,118 shares changed hands during mid-day trading, a decline of 78% from the average daily volume of 106,162 shares. The stock had previously closed at $1.90.

Wall Street Analyst Weigh In

Several research firms have issued reports on ISPC. Weiss Ratings restated a “sell (e+)” rating on shares of iSpecimen in a research report on Friday, July 17th. Wall Street Zen upgraded iSpecimen to a “sell” rating in a report on Saturday, May 2nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

iSpecimen Stock Up 3.3%

The stock has a market cap of $2.87 million, a P/E ratio of -0.03 and a beta of 1.63. The company has a 50-day simple moving average of $2.60 and a two-hundred day simple moving average of $6.63.

iSpecimen (NASDAQ:ISPC) last issued its earnings results on Friday, May 15th. The company reported ($6.66) earnings per share (EPS) for the quarter. iSpecimen had a negative return on equity of 584.65% and a negative net margin of 1,080.16%.The firm had revenue of $0.16 million during the quarter.

Hedge Funds Weigh In On iSpecimen

An institutional investor recently bought a new stake in iSpecimen stock. Scientech Research LLC acquired a new stake in shares of iSpecimen Inc. (NASDAQ:ISPC) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 29,488 shares of the company’s stock, valued at approximately $38,000. Scientech Research LLC owned about 0.30% of iSpecimen at the end of the most recent quarter. 13.62% of the stock is currently owned by hedge funds and other institutional investors.

About iSpecimen

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.